Now Accepting Applications for 2019 Advocacy Fellows!

Email Updates

Search form

You are here

Home

IPM 032 (DREAM)

Status
Ongoing
Phase
Open Label
Objective

DREAM (Dapivirine Ring Access and Monitoring), or IPM 032, is a follow-on Open-Label Trial to Assess Continued Safety of and Adherence to the Dapivirine (25mg) Vaginal Ring-004 in Healthy, HIV-Negative Women 

Prevention Option(s)
Microbicides
Study Design
Open label
Arms and Assigned Interventions
Description
Each participant will engage in the screening process for up to 45 days prior to enrollment and will use the monthly Dapivirine Vaginal Ring for a period of up to 12 months.
Mode of Delivery
Ring
Products
Dapivirine Ring
ARMs
Experimental
Results
HIV INCIDENCE AND ADHERENCE IN DREAM: AN OPEN-LABEL TRIAL OF DAPIVIRINE VAGINAL RING
Official Code
NCT02862171
Trial Sponsors
International Partnership for Microbicides, Inc.
August 2016
December 2018
Enrollment
1 400
18
Years
40
Years
Population
Women
Sites

Madibeng Centre for Research

Brits
South Africa

Qhakaza Mbokodo Research Clinic

Ladysmith
South Africa

MatCH Edendale Research Center

Pietermaritzburg, Kwa-Zulu Natal
South Africa

Desmond Tutu HIV Foundation - Masiphumelele

Masiphumelele
South Africa

Ndlovu Medical Centre

Limpopo
South Africa

MRC/UVRI Uganda Research Unit on AIDS

Masaka
Uganda